American Research Corporation
Quick facts
Marketed products
- paritaprevir/ritonavir/ombitasvir + dasabuvir +/- ribavirin · Virology / Hepatology
This combination inhibits hepatitis C virus (HCV) replication by blocking multiple viral enzymes essential for viral protein processing and RNA synthesis.
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors: